News

Seth Lederman, CEO of Tonix Pharmaceuticals, discusses their diverse research and development pipeline-including potential therapies for fibromyalgia, cocaine intoxication, and PTSD.

Cherry-picking a small group here and a dementia risk factor there won't reflect the way that dementia affects people from every walk of life, writes CEO & Founder of Savonix, Mylea Charvat.

Click the title above to open the Applied Clinical Trials November 2019 issue in an interactive PDF format.

Exploring the nation’s opportunities for growth and the initiatives undertaken to build an attractive clinical trials ecosystem for early stage research.

Roundtable gathers industry experts to discuss the guidance update’s early implementation and the shift toward risk-based study execution approaches.

A compilation of recently released news briefs that pertain to the clinical trials industry.

Outlining the three critical challenges that need to be addressed to make personalized cancer treatment a reality.

Additional policies for registering clinical studies in U.S. and Europe aim to expand access to research data and provide timely information for patients on promising, new treatments.

David Freeman, general manager, Information Ventures, for Quest Diagnostics, talks about the company's use of lab data to create an effective partnership for pharma and biotech companies.

As China’s pharma industry continues to evolve and mature, it is hoped overseas expansion and greater innovation will be exported to serve the interests of patients.

A shift in emphasis in healthcare strategy could reduce attention and funding to therapy and impose tougher controls over research projects, or possible mean a boost for innovative healthcare. A look at where these trends may go.

For drug developers, oncology therapeutics arguably represent both the greatest opportunity and challenge for putting patients at the center. This ebook covers series strategies for Advancing Oncology Drug Development with ePRO Solutions.

After a court case rehashes the issue of excessive secrecy in trial data, drug firms maintain their objections over releasing data on their products.

The time to stop hammering square pegs into round holes in terms of design strategy has come, as sponsors embrace an adaptive supply chain approach.

With a month left to join one of the 24 ERNs, Peter O'Donnell writes that this initiative is a welcomed demonstration of how cooperation can function in the common interest.